Mannkind Corp (MNKD) 3.65 $MNKD
3 Reasons Why Afrezza's Launch Has Been So Disappointing
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 25, 11:04AM CDT
Source: Mannkind. For a drug that many hoped would reach blockbuster status, MannKind Corporation 's inhaled insulin Afrezza is off to an awful start. The promise and potential of this medication continues to look huge, and the product...
MNKD: 3.65 (+0.34)
BUYINS.NET: HDB, CRM, MNKD, PRU, NXTM, BKD Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Aug 25, 7:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of HDFC Bank Ltd (NYSE:HDB), Salesforce.com Inc (NYSE:CRM), Mannkind Corp (NASDAQ:MNKD), Prudential Financial Inc (NYSE
RU), NxStage Medical Inc (NASDAQ:NXTM), BROOKDALE SENIOR LIVING INC. (NYSE:BKD) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
NXTM: 17.85 (-0.07), PRU: 77.46 (+3.24), HDB: 57.61 (+0.42), BKD: 27.26 (-0.03), MNKD: 3.65 (+0.34), CRM: 68.52 (+3.34)
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Aug 23, 1:37PM CDT
With earnings season behind us, many investors are wondering which stocks should be queued for a buy in the healthcare market. On this Industry Focus episode, Motley Fool's Kristine Harjes and contributor Todd Campbell discuss second-quarter...
BIIB: 298.25 (+16.51), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), REGN: 535.47 (+36.45)
The 3 Most Disappointing Drug Launches of All Time
Dan Caplinger, Todd Campbell, and Cheryl Swanson, The Motley Fool - Motley Fool - Sun Aug 23, 9:57AM CDT
Source: TaxFix.co.uk, Flickr. Pharmaceutical and biotech companies pride themselves on developing treatments with blockbuster potential, and the most successful drugs can bring in tens of billions of dollars in revenue over time. Yet sometimes,...
VVUS: 1.12 (+0.07), SNY: 49.13 (+1.30), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04)
MannKind Financial Woes Escalate on Failed Debt Settlement
at The Street - Thu Aug 20, 8:14AM CDT
The slow commercial launch of Afrezza, MannKind's inhaled mealtime insulin, continues to be the root cause of the company's balance-sheet woes.
MNKD: 3.65 (+0.34)
Critical Alerts For PayPal Holdings Inc., MannKind, Sysco Corporation, Transocean and Sarepta Therapeutics Released By InvestorsObserver
PR Newswire - Mon Aug 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PYPL, MNKD, SYY, RIG and SRPT.
RIG: 11.60 (-0.60), SRPT: 34.17 (+1.59), SYY: 39.95 (+0.91), PYPL: 33.17 (+0.47), MNKD: 3.65 (+0.34)
3 Biotech Stocks That Are Getting a Heckuva Lot Riskier
Todd Campbell, The Motley Fool - Motley Fool - Sun Aug 16, 8:41AM CDT
Source: Flickr user State Farm A never-ending stream of new drugs making their way to market makes biotech stocks especially prone to jaw-dropping pops and drops, and the industry's all-or-nothing nature could become especially apparent to...
IRWD: 11.00 (+0.41), AEGR: 17.70 (+0.68), MNKD: 3.65 (+0.34)
3 Biotech Stocks Wall Street Hates
George Budwell, The Motley Fool - Motley Fool - Sat Aug 15, 7:59AM CDT
Short sellers have been piling into healthcare stocks this year, especially among companies with comparatively small market caps. While the global economic headwinds such as the Greek and Puerto Rican financial meltdowns have potentially been major...
NWBO: 7.87 (+0.18), ADAP: 11.45 (unch), MNKD: 3.65 (+0.34)
MannKind (MNKD) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 11:20AM CDT
MannKind (MNKD) reported a loss of 7 cents per share in the second quarter of 2015.
AMAG: 63.26 (+4.30), LLY: 81.10 (+2.84), SNY: 49.13 (+1.30), MNKD: 3.65 (+0.34)
MannKind (MNKD) Stock Rallying in After-Hours Trading on Earnings Beat
at The Street - Mon Aug 10, 3:04PM CDT
MannKind (MNKD) reported its fiscal 2015 second quarter earnings results before the opening bell today that beat analysts' estimates.
MNKD: 3.65 (+0.34)
MannKind Up 6.7%, Shares Break Through Resistance (MNKD)
Comtex SmarTrend(R) - Mon Aug 10, 10:43AM CDT
MannKind (NASDAQ:MNKD) is one of today's best performing low-priced stocks, up 6.7% to $4.25 on 1.2x average daily volume. MannKind has traded 5.9 million shares thus far today, vs. average volume of 5.1 million shares per day. The stock has outperformed the Dow (6.7% to the Dow's 1.2%) and outperformed the S&P 500 (6.7% to the S&P's 1.1%) during today's trading.
MNKD: 3.65 (+0.34)
Mannkind Announces Addition of Chief Medical Officer
GlobeNewswire - Mon Aug 10, 8:15AM CDT
MannKind Corporation (NASDAQ:MNKD) today announced the appointment of Dr. Raymond Urbanski as its Chief Medical Officer. As Chief Medical Officer, Dr. Urbanski will lead MannKind's overall drug development activities and will be a member of the Executive Leadership Team.
MNKD: 3.65 (+0.34)
MannKind Corporation Reports 2015 Second Quarter Financial Results
GlobeNewswire - Mon Aug 10, 7:01AM CDT
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2015.
MNKD: 3.65 (+0.34)
Biotech Stock Mailbag: Controversial Stocks Revisited
at The Street - Fri Aug 07, 5:10AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RGLS: 7.20 (+0.42), RMTI: 11.58 (+0.43), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), KERX: 5.87 (+0.26)
Why MannKind Got the Unkind Treatment From Investors in July
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 05, 11:16AM CDT
Shares of MannKind , a biopharmaceutical company focused on developing medicines to treat diabetes, plunged 25% in July based on data from S&P Capital IQ following the release of disappointing sales results for its only approved drug Afrezza...
MNKD: 3.65 (+0.34)
Critical Alerts For MannKind, Sarepta Therapeutics, NXP Semiconductors, Rockwell Medical and Micron Released By InvestorsObserver
PR Newswire - Tue Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, SRPT, NXPI, RMTI and MU.
MU: 14.42 (+0.15), SRPT: 34.17 (+1.59), RMTI: 11.58 (+0.43), NXPI: 85.02 (+4.18), MNKD: 3.65 (+0.34)
MannKind Corporation to Hold 2015 Second Quarter Financial Results Conference Call on August 10, 2015
GlobeNewswire - Tue Aug 04, 1:10AM CDT
MannKind Corporation (Nasdaq:MNKD) will release its 2015 second quarter financial results on Monday, August 10, 2015 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 9:00 AM (Eastern Time) on August 10, 2015.
MNKD: 3.65 (+0.34)
Building a Sweet 16 Portfolio, Part 2
at The Street - Sat Aug 01, 9:00AM CDT
A little of this, a little of that to create a nice yield.
EYES: 9.14 (+0.32), PNNT: 7.07 (+0.07), ACU: 17.31 (-0.52), CUBI: 23.36 (+0.85), ABX: 6.55 (-0.44), NMM: 6.98 (-0.18), XOM: 72.50 (+3.79), YPF: 19.75 (+0.73), MNKD: 3.65 (+0.34), OHGI: 1.35 (-0.05), ASTC: 1.87 (+0.08), MHR: 0.84 (+0.05), DFT: 27.14 (+0.57), BIDU: 142.40 (+5.41), DHT: 7.00 (+0.19), GDP: 0.60 (unch), NEWT: 16.97 (+0.46), ARR: 21.29 (+0.49), TWTR: 25.03 (+0.65)
MannKind Triples Production Capacity for Afrezza
GlobeNewswire - Fri Jul 31, 8:00AM CDT
MannKind Corporation (Nasdaq:MNKD) today announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza(R) (insulin human) inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.
MNKD: 3.65 (+0.34)
3 Reasons Why Afrezza's Launch Has Been So Disappointing
Brian Feroldi, The Motley Fool - Motley Fool - Tue Aug 25, 11:04AM CDT
Source: Mannkind. For a drug that many hoped would reach blockbuster status, MannKind Corporation 's inhaled insulin Afrezza is off to an awful start. The promise and potential of this medication continues to look huge, and the product...
MNKD: 3.65 (+0.34)
BUYINS.NET: HDB, CRM, MNKD, PRU, NXTM, BKD Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Aug 25, 7:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of HDFC Bank Ltd (NYSE:HDB), Salesforce.com Inc (NYSE:CRM), Mannkind Corp (NASDAQ:MNKD), Prudential Financial Inc (NYSE
RU), NxStage Medical Inc (NASDAQ:NXTM), BROOKDALE SENIOR LIVING INC. (NYSE:BKD) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: NXTM: 17.85 (-0.07), PRU: 77.46 (+3.24), HDB: 57.61 (+0.42), BKD: 27.26 (-0.03), MNKD: 3.65 (+0.34), CRM: 68.52 (+3.34)
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Aug 23, 1:37PM CDT
With earnings season behind us, many investors are wondering which stocks should be queued for a buy in the healthcare market. On this Industry Focus episode, Motley Fool's Kristine Harjes and contributor Todd Campbell discuss second-quarter...
BIIB: 298.25 (+16.51), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), REGN: 535.47 (+36.45)
The 3 Most Disappointing Drug Launches of All Time
Dan Caplinger, Todd Campbell, and Cheryl Swanson, The Motley Fool - Motley Fool - Sun Aug 23, 9:57AM CDT
Source: TaxFix.co.uk, Flickr. Pharmaceutical and biotech companies pride themselves on developing treatments with blockbuster potential, and the most successful drugs can bring in tens of billions of dollars in revenue over time. Yet sometimes,...
VVUS: 1.12 (+0.07), SNY: 49.13 (+1.30), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04)
MannKind Financial Woes Escalate on Failed Debt Settlement
at The Street - Thu Aug 20, 8:14AM CDT
The slow commercial launch of Afrezza, MannKind's inhaled mealtime insulin, continues to be the root cause of the company's balance-sheet woes.
MNKD: 3.65 (+0.34)
Critical Alerts For PayPal Holdings Inc., MannKind, Sysco Corporation, Transocean and Sarepta Therapeutics Released By InvestorsObserver
PR Newswire - Mon Aug 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PYPL, MNKD, SYY, RIG and SRPT.
RIG: 11.60 (-0.60), SRPT: 34.17 (+1.59), SYY: 39.95 (+0.91), PYPL: 33.17 (+0.47), MNKD: 3.65 (+0.34)
3 Biotech Stocks That Are Getting a Heckuva Lot Riskier
Todd Campbell, The Motley Fool - Motley Fool - Sun Aug 16, 8:41AM CDT
Source: Flickr user State Farm A never-ending stream of new drugs making their way to market makes biotech stocks especially prone to jaw-dropping pops and drops, and the industry's all-or-nothing nature could become especially apparent to...
IRWD: 11.00 (+0.41), AEGR: 17.70 (+0.68), MNKD: 3.65 (+0.34)
3 Biotech Stocks Wall Street Hates
George Budwell, The Motley Fool - Motley Fool - Sat Aug 15, 7:59AM CDT
Short sellers have been piling into healthcare stocks this year, especially among companies with comparatively small market caps. While the global economic headwinds such as the Greek and Puerto Rican financial meltdowns have potentially been major...
NWBO: 7.87 (+0.18), ADAP: 11.45 (unch), MNKD: 3.65 (+0.34)
MannKind (MNKD) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Tue Aug 11, 11:20AM CDT
MannKind (MNKD) reported a loss of 7 cents per share in the second quarter of 2015.
AMAG: 63.26 (+4.30), LLY: 81.10 (+2.84), SNY: 49.13 (+1.30), MNKD: 3.65 (+0.34)
MannKind (MNKD) Stock Rallying in After-Hours Trading on Earnings Beat
at The Street - Mon Aug 10, 3:04PM CDT
MannKind (MNKD) reported its fiscal 2015 second quarter earnings results before the opening bell today that beat analysts' estimates.
MNKD: 3.65 (+0.34)
MannKind Up 6.7%, Shares Break Through Resistance (MNKD)
Comtex SmarTrend(R) - Mon Aug 10, 10:43AM CDT
MannKind (NASDAQ:MNKD) is one of today's best performing low-priced stocks, up 6.7% to $4.25 on 1.2x average daily volume. MannKind has traded 5.9 million shares thus far today, vs. average volume of 5.1 million shares per day. The stock has outperformed the Dow (6.7% to the Dow's 1.2%) and outperformed the S&P 500 (6.7% to the S&P's 1.1%) during today's trading.
MNKD: 3.65 (+0.34)
Mannkind Announces Addition of Chief Medical Officer
GlobeNewswire - Mon Aug 10, 8:15AM CDT
MannKind Corporation (NASDAQ:MNKD) today announced the appointment of Dr. Raymond Urbanski as its Chief Medical Officer. As Chief Medical Officer, Dr. Urbanski will lead MannKind's overall drug development activities and will be a member of the Executive Leadership Team.
MNKD: 3.65 (+0.34)
MannKind Corporation Reports 2015 Second Quarter Financial Results
GlobeNewswire - Mon Aug 10, 7:01AM CDT
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2015.
MNKD: 3.65 (+0.34)
Biotech Stock Mailbag: Controversial Stocks Revisited
at The Street - Fri Aug 07, 5:10AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RGLS: 7.20 (+0.42), RMTI: 11.58 (+0.43), MNKD: 3.65 (+0.34), ARNA: 2.72 (+0.04), KERX: 5.87 (+0.26)
Why MannKind Got the Unkind Treatment From Investors in July
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 05, 11:16AM CDT
Shares of MannKind , a biopharmaceutical company focused on developing medicines to treat diabetes, plunged 25% in July based on data from S&P Capital IQ following the release of disappointing sales results for its only approved drug Afrezza...
MNKD: 3.65 (+0.34)
Critical Alerts For MannKind, Sarepta Therapeutics, NXP Semiconductors, Rockwell Medical and Micron Released By InvestorsObserver
PR Newswire - Tue Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, SRPT, NXPI, RMTI and MU.
MU: 14.42 (+0.15), SRPT: 34.17 (+1.59), RMTI: 11.58 (+0.43), NXPI: 85.02 (+4.18), MNKD: 3.65 (+0.34)
MannKind Corporation to Hold 2015 Second Quarter Financial Results Conference Call on August 10, 2015
GlobeNewswire - Tue Aug 04, 1:10AM CDT
MannKind Corporation (Nasdaq:MNKD) will release its 2015 second quarter financial results on Monday, August 10, 2015 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 9:00 AM (Eastern Time) on August 10, 2015.
MNKD: 3.65 (+0.34)
Building a Sweet 16 Portfolio, Part 2
at The Street - Sat Aug 01, 9:00AM CDT
A little of this, a little of that to create a nice yield.
EYES: 9.14 (+0.32), PNNT: 7.07 (+0.07), ACU: 17.31 (-0.52), CUBI: 23.36 (+0.85), ABX: 6.55 (-0.44), NMM: 6.98 (-0.18), XOM: 72.50 (+3.79), YPF: 19.75 (+0.73), MNKD: 3.65 (+0.34), OHGI: 1.35 (-0.05), ASTC: 1.87 (+0.08), MHR: 0.84 (+0.05), DFT: 27.14 (+0.57), BIDU: 142.40 (+5.41), DHT: 7.00 (+0.19), GDP: 0.60 (unch), NEWT: 16.97 (+0.46), ARR: 21.29 (+0.49), TWTR: 25.03 (+0.65)
MannKind Triples Production Capacity for Afrezza
GlobeNewswire - Fri Jul 31, 8:00AM CDT
MannKind Corporation (Nasdaq:MNKD) today announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza(R) (insulin human) inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.
MNKD: 3.65 (+0.34)
